Skip To Main Content
Bronwyn Thompson on Muck Rack

Bronwyn Thompson

Sydney
As seen in: Wiley, Wiley Online Library, Stuff.co.nz, Sydney Morning Herald, Biomed Central (BMC), Flipboard, The Age, Constant Contact, New Atlas, The Canberra Times and
former journalist, zoologist in training
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bronwyn

Contact Bronwyn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Low back pain cut by 50% in first swimming clinical trial

|
By Bronwyn Thompson
| refractor.io
In the first study of its kind, scientists have found that swimming can provide relief from chronic low back pain. The trial suggests this exercise is clinically effective for treating this hard-to-target condition. Researchers at Macquarie University in Australia have demonstrated for the first time that a consistent swimming regimen can reduce low back pain, providing all-important scientific evidence for the physical activity often suggested by clinicians.
Open in Who Shared View Duplicates (4) Issue with article?

How your brain learns who to avoid after a bad experience

|
By Bronwyn Thompson
| refractor.io
Scientists have discovered a neural mechanism that shapes our aversion to select individuals, opening the door to understanding how the brain drives our dislike of others. A team including researchers from the University of Tokyo made these findings in a study on mice, and what happens in their brains when they encounter an individual they see as a threat.
Open in Who Shared Issue with article?

Once-daily LDL cholesterol-smashing pill gets FDA approval

|
By Bronwyn Thompson
| Gear Open
The US Food and Drug Administration (FDA) has just approved a game-changing cholesterol drug, the first of its kind in a class that's otherwise administered by injection. Lipfendra, or enlicitide, blocks the PCSK9 protein, which drives cholesterol levels up and increases the risk of cardiovascular disease.
Open in Who Shared Issue with article?
See all 1,052 licensed articles (1,128 Total)